Docket No.: 102258.133 US2 PATENT/OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

David S. GARVEY

Serial No. 10/695,644 : Group Art Unit: 1614

Filed: October 29, 2003 : Examiner:

For: NITROSATED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES.

COMPOSITIONS AND METHODS OF USE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R.§ 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of

Serial No. 10/695,644

publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

Applicants' representative certifies that the enclosed documents were cited in a communication from the European Patent Office in a counterpart foreign application.

ecember 15, 2004

No fee is believed to be required; however, the Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,

WILMER CUTLER PICKERING HALE AND DORR LLP

Edward D. Grieff Registration No. 38

1455 Pennsylvania Avenue, NW Washington, DC 20004

TEL 202.942.8400 EDG/mgm

FAX 202.942.8484

Date:

SHEET 1 OF 1 ATTY. DOCKET NO. SERIAL NO. 102258.133 US2 10/695,644 INFORMATION DISCLOSURE CITATION IN AN **APPLICATION** (PTO-1449) APPLICANT David S. Garvey FILING DATE **GROUP** October 29, 2003 1614 **U.S. PATENT DOCUMENTS EXAMINER'S FILING INITIALS** PATENT NO. DATE NAME **CLASS** SUBCLASS DATE FOREIGN PATENT DOCUMENTS **EXAMINER'S** Translation PATENT NO. DATE **SUBCLASS** INITIALS COUNTRY **CLASS** No 02/22/01 WIPO WO 01/12584 X OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Kakoki, Masao et al. January 1999. "Effects of Vasodilatory β-Adrenoceptor Antagonists on Endothelium-Derived Nitric Oxide Release in Rat Kidney." Hypertension. Vol. 33, part II. pp. 467-471. Brehm, B. R. et al. 2001. "Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells." Cardiovascular Research. Vol. 49. pp. 430-439. September 7, 2004. Supplementary European Search Report from European Patent Application No. 02766876.3. **EXAMINER** DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.